A first prototype of a novel endovenous therapy technology (SnakeBack, LSO Medical) integrated with a laser ablation platform was revealed earlier this year at the Charing Cross Symposium (CX; 24-27 April, London, UK) by Philippe Rochon, president of LSO...
Boston Scientific has signed an agreement to acquire Veniti, a privately-held company in Fremont, USA which developed and commercialised the Vici venous stent system for treating venous obstructive disease. Boston Scientific has been an investor in Veniti since 2016 and...
NexGen Medical Systems, Inc., a US medical device company, has announced the successful completion of the first human use of their XCOIL large vessel (18mm) thrombectomy system for the treatment of deep vein thrombosis (DVT). The new device, an expansion...
A new analysis has identified patient populations with cancer-associated venous thromboembolism (VTE) who could benefit from treatment with oral anticoagulant edoxaban, taken once daily. Daiichi Sankyo has announced the publication of a new analysis, focusing on the clinical presentation, course...
A Cambridge study has found that most inpatients with leg ulcers were not referred to a vascular surgery team, indicating a need to improve pathways of care for inpatients with leg ulcerations. The results of the study conducted at Addenbrooke’s...
Venclose has announced the closing of an oversubscribed Series B round of financing from new and existing investors. Proceeds from the financing will be used to support new product development, expansion of manufacturing capabilities and general corporate purposes. The company...
EchoNous Vein (EchoNous), an ultrasound-based tool designed specifically for nurses to improve peripheral IV catheter placements, has received US Food and Drug Administration (FDA) approval. A company release explains that EchoNous Vein provides immediate, clear images at depths from 1–5cm...

Alun Davies

Alun Davies is a Welsh-born leading expert in the venous field, one of the Editors-in-Chief of Venous News, and currently in the spotlight as chief investigator of the EVRA ulcer trial. In this profile, Davies talks about the implications...
Highlights: Landmark EVRA trial provides first Level 1 evidence for early venous ablation Ultrasound-guided foam sclerotherapy of small saphenous vein as effective as endovenous laser ablation for venous clinical severity score and quality of life at one year Rick...
Highlights: Landmark EVRA trial provides first Level 1 evidence for early venous ablation Ultrasound-guided foam sclerotherapy of small saphenous vein as effective as endovenous laser ablation for venous clinical severity score and quality of life at one year Rick...
An analysis of post-thrombotic disease patients who received a nitinol stent has found that ultrasound surveillance should occur at frequent intervals up to two weeks post-procedure to predict risk of re-intervention. The results of the study were presented at the...
A new randomised controlled trial evaluated the preventative effect of compression stockings during pregnancy on the incidence of varicose veins as well as venous thromboembolism, with results suggesting that women with no venous disease using compression stocking during pregnancy...
BTG has announced a strategic partnership with the PERT Consortium to advance the science of pulmonary embolism treatment and promote the implementation of PERT programmes across the USA. The partnership was announced at the annual PERT Consortium Meeting (22–23...
The annual census of UK consultants and higher speciality trainees—Focus on Physicians 2017–18—indicates that more than half of all consultants and two thirds of trainees reported frequent gaps in trainees’ rotas, with one in five respondents saying these are...
The one-year results of the ACCESS PTS trial have shown that EKOS therapy (BTG) statistically improves post-thrombotic syndrome scores and sequelae as well as quality of life outcomes. Presenting the data at the Charing Cross Symposium (24–27 April, London,...
Cees Wittens writes for Venous News about the current state of deep venous obstruction interventions, what we might expect in the near future, and what is needed in terms of new technology, strategy and policy in 2018. In general, everybody...
Treatment of patients with pelvic venous disorders is a “controversial topic,” Kathleen Gibson (Lake Washington Vascular Surgeons, Bellevue, USA) said at the Charing Cross Symposium (CX; 24–27 April, London, UK), as there is “no consensus on the best mode...
New data from the MERCURY PE study have shown that patients with low-risk pulmonary embolism who were treated with the direct oral anticoagulant rivaroxaban, trade name Xarelto (Janssen Pharmaceutical), and discharged from the emergency department had significantly reduced time...
St Paul's Hospital in Vancouver, Canada has successfully completed two implantations of the VenusP-Valve (Venous Medtech), a self-expanding pulmonary valve. This is the first appearance of Venus Medtech's transcatheter valve products in North America. Although surgical treatment of congenital heart disease has evolved...
Major global wound care company Acelity is acquiring Crawford Healthcare, a growing UK-based advanced wound care and dermatology company, along with all of its assets. The companies announced the acquisition today, but did not disclose the terms of the...
Countries in the European Union have long been the first to receive new innovations in medical technology, as the EU’s Medical Device Directive (MDD) provided quicker routes to implementation of new devices than its equivalent in the USA, the...
Data presented at the Charing Cross Symposium (24–27 April, London, UK) indicate that a rounder post-stent lumen shape has a positive correlation to 12-month patient improvement, placing emphasis on the change of lumen shape from pre- to post-stent and...
Vesper Medical, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, has announced that it completed its Series A financing, totaling US$10.5 million. Major participants in the Series A financing included New Enterprise Associates and Quaker...
Inari Medical have announced the presentation of results from its FlowTriever Pulmonary Embolectomy (FLARE) clinical study that evaluated the safety and effectiveness of the FlowTriever Retrieval/Aspiration System for the treatment of pulmonary embolism. The results were presented by Thomas Tu, an...
According to a debate at the Charing Cross Symposium (CX; 24–27 April, London, UK), the vast majority of CX delegates disagree with the view that the ATTRACT trial has provided the definitive answer on the use of pharmacomechanical catheter-directed...
For many venous specialists, dedicated venous stents represent the future—and the promise of an ideal venous stent on the horizon is a central topic of discussion. In this article, Rick de Graaf reviews the recent history of venous stenting...
Preliminary data from the Fovelass trial, presented at the Charing Cross Symposium (24–27 April, London, UK) by Claudine Hamel-Desnos (Caen, France) show that at one-year follow-up, the rate of occlusion of the small saphenous vein is lower after ultrasound...
The first full results of the Early Venous Reflux Ablation (EVRA) ulcer study were presented at the Charing Cross Symposium (CX; 24-27 April, London, UK). The presentation was accompanied by simultaneous publication in the New England Journal of Medicine...
Cardiva Medical, a vascular closure device company, today announced it has received approval from the US Food and Drug Administration (FDA) for an expanded indication of the VASCADE Vascular Closure System. Already approved for use in arterial closure, the...
The Royal Society of Medicine Venous Forum council has created a document that is intended to aid physicians when treating patients with leg ulcers. The document, “Management of Patients with Leg Ulcers”, indicates that urgent action is needed to ensure that...
Intravascular ultrasound (IVUS) imaging technology provides the current gold standard technique for detection and characterisation of venous disease, Erin Murphy writes. In this article, Murphy discusses the limitations of venography and outlines the use of IVUS for optimised outcomes...
Venture-backed medical device company Inari Medical has announced the close of a Series C financing totaling US$27 million. The company plans to use the capital to commercialise its catheter devices for the treatment of venous thromboembolism. The financing was led by new...
Medical device company Plus medica has announced that 10 patients have been treated with the company’s blueflow Venous Stent. The first cases were performed by Michael Lichtenberg, Klinikum Arnsberg, Arnsberg, Germany, and Nils Kucher, University Hospital Zurich, Zurich, Switzerland. The...
The handheld medical imaging system HyperView (HyperMed Imaging) has received CE mark, allowing for distribution in Europe. The system is designed to detect perfusion of superficial tissue in support of wound care. The HyperView System is a fast, handheld, battery...
Representation is essential in the constantly changing medical landscape that healthcare professionals are facing. The American College of Phlebology (ACP) has begun several new initiatives recently to improve the representation of venous and lymphatic health care providers within the...
The deep venous world is wrestling with the question: To stent or not to stent. While the availability of new specialised venous stents is boosting popularity for the technique, there are some reservations about the appropriateness and risks of...
Following the announcement of receiving the CE mark in early 2018, ab medica has now reported the first-in man usage of its blueflow Venous Stent. The company signed an exclusive distribution agreement for the blueflow Venous Stent with plus medica...
The common diagnosis of post-thrombotic syndrome (PTS) includes a history of deep venous thrombosis and a Villalta Scale score of four or above. However, a recent study conducted by JOBST Vascular Institute of ProMedica, examining whether misclassification bias might occur...
The International Union of Phlebology World Congress (UIP) will head to Turkey in 2021 after Istanbul successfully won the bid to be the host city of the next meeting. The battle for the host city of UIP 2021 was hotly...
Highlights: CX presents comprehensive Venous Controversies programme UIP audience votes against stenting as standard for deep vein obstruction Setting the record straight: Clarifying the misconceptions of the ATTRACT trial Erin Murphy: Use of IVUS to optimise outcomes in venous...
Highlights: CX presents comprehensive Venous Controversies programme UIP audience votes against stenting as standard for deep vein obstruction Setting the record straight: Clarifying the misconceptions of the ATTRACT trial Erin Murphy: Use of IVUS to optimise outcomes in venous...
Rick de Graaf speaks to Venous News about complications from venous stenting, including causes and best treatment approaches for reinterventions after stenting.
A special session during the pre-conference Day of Innovation and Science at the American Venous Forum annual meeting (AVF; 20–23 February, Tucson, USA) presented the rare occasion for attendees to listen to and interact directly with the principal investigator...
A recent study on iliac vein stenting following catheter-directed thrombolysis for deep vein thrombosis (DVT) has shown that technical and clinical success  require high thrombus clearance rates, and stenting below the inguinal ligament does not have an adverse outcome...
After five years, the board of the European College of Phlebology is changing, announced Eberhard Rabe (University of Bonn, Bonn, Germany) at the European Vascular Course (EVC; 4–6 March, Maastricht, The Netherlands). The election is to be held among...
The blueflow Venous Stent (plus medica) received the CE mark in January 2018. The news was announced via a company release in March. The blueflow Venous Stent, developed and manufactured in Germany is a two nitinol wire braided stent used to...
UK-based Inotec AMD Limited has announced the appointment of Craig Kennedy as its new chief executive officer on 3 March 2018. Inotec AMD is a maker of mobile medical devices designed to heal chronic, hypoxic wounds that afflict millions of...
At the American Venous Forum (AVF; 20–23 February, Tucson, USA), a session on venous leg ulcers turned to possible future treatment strategies as Kathleen Gibson (Lake Washington Vascular Surgeons, Bellevue, USA) spoke about off-label uses of cyanoacrylate and polidocanol...
Efficacy data from the Arnsberg Registry at 12 months are promising, with high primary patency rates for a dedicated venous stent. Presenting the data at the Leipzig Interventional Course (LINC; 30 January­–2 February, Leipzig, Germany), the registry’s principal investigator Michael...

Armando Mansilha

Armando Mansilha is professor of Angiology and Vascular Surgery, Faculty of Medicine at the University of Porto, Porto, Portugal. In this interview with Venous News, he speaks about his early work and mentors, the biggest developments in venous medicine...
The Food and Drug Administration (FDA) has today issued the final rule on “human subject protection; acceptance of data from clinical investigations for medical devices”. The rule updates the FDA’s standards for accepting clinical data from clinical investigations conducted...
“Endovascular reconstruction of the chronically obstructed iliocaval venous tract with stents is technically feasible, minimally invasive and has an acceptable safety rate, said James Budge, Department of Vascular Surgery, Guy’s and St Thomas’, London, UK. “Patients who underwent this procedure...
Following the publication of the ATTRACT trial in the New England Journal of Medicine (NEJM) in December 2017, Venous News spoke to experts in the field to analyse the data and formulate future research questions. One of the interesting...
Highlights: Published ATTRACT data call into question validity of the Villalta scale Brave Dreams trial finds venoplasty “safe, but largely ineffective” for MS patients Johann C Ragg: Percutaneous valvuloplasty Nicholas Osborne: VQI Varicose Vein Registry Profile: Armando Mansilha https://venousnews.com/wp-content/uploads/sites/19/2018/02/Venous-News-4-low-res-US.pdf

Venous News 4 – January 2018

Highlights: Published ATTRACT data call into question validity of the Villalta scale Brave Dreams trial finds venoplasty “safe, but largely ineffective” for MS patients Johann C Ragg: Percutaneous valvuloplasty Nicholas Osborne: VQI Varicose Vein Registry Profile: Armando Mansilha https://venousnews.com/wp-content/uploads/sites/19/2018/02/Venous-News-4-low-res-EU.pdf
LimFlow has announced completion of enrolment of the original 10-patient cohort in the US feasibility study of the LimFlow percutaneous deep vein arterialisation system. The company also announced that the US FDA has accepted the company’s proposal to expand...
Medtronic has announced the initiation of its investigational device exemption (IDE) study for the Abre venous self-expanding stent system. The ABRE IDE Study will evaluate the safety and effectiveness of the Abre stent in patients with iliofemoral venous outflow...
Members of the venous community have had a longstanding commitment to collecting and analysing the outcomes of venous procedures. The Vascular Quality Initiative (VQI) Varicose Vein Registry (VVR) grew out of a previous registry established by the American Venous...
Venous specialists from around the globe will meet in Melbourne for the much anticipated 2018 World Congress of Phlebology (UIP; 4–8 February, Melbourne, Australia) hosted by the Australasian College of Phlebology.  The president of UIP (International Union of Phlebology), Nick...
Compression therapy for venous ulcers requires accurate monitoring to ensure successful delivery and the desired compression dose. However, according to a study presented at the American College of Phlebology annual meeting (ACP; 2–5 November, Austin, USA), the level of...
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration's (FDA) mini-sentinel assessment, confirming the positive safety and efficacy profile of Xarelto (rivaroxaban) established in the phase III ROCKET AF clinical trials,...
Daiichi Sanyoko has announced the results from their Hokusai-VTE CANCER trial evaluating the direct oral anticoagulant edoxaban for treatment of venous thromboembolism (VTE) in cancer patients. The Hokusai-VTE CANCER study is a phase 3b, prospective, randomised, open-label, blind end-point study...
The European Board of Phlebology has announced that the European Union of Medical Specialists (UEMS) have adopted the European training requirements presented by Jean-Jérôme Guex, president of the newly created Board. The development is the result of a European...
Global specialist healthcare company BTG has highlighted the commencement of the KNOCOUT PE study. The KNOCOUT PE study will measure how hospitals and patients are benefitting from a new standard of care in the treatment of pulmonary embolism utilising...
Venous stenting has evolved over the last 15 years, quickly becoming an established procedure, with Class II recommendations from the American Heart Association and American College of Phlebology. Speaking at the Vascular Society of Great Britain and Ireland’s Annual...
Leg ulceration is the poor relation of vascular disease, yet, as Sophie Renton writes, it is a very common problem. It is estimated that 1/1,000 people in the UK will have a leg ulcer at some stage in their lives. Leg ulcers become...
More than 25% of the adult population is affected by varicose veins, with more than a 15% prevalence of chronic venous insufficiency (C3–C6), which induces a considerable burden on the health of these patients. The Bonn Vein Study found that 21% of the...
At the THE VEINS at VIVA meeting (10–11 September, Las Vegas, USA), Esther Kim (Vanderbilt University Medical Center, Nashville, USA) gave a presentation on venous thrombosis in unusual locations, noting that such thromboses tend to occur in younger patients and those with malignancy,...
At THE VEINS at VIVA meeting (10–11 September 2017, Las Vegas, USA), James Froehlich, University of Michigan, Ann Arbor, USA, reviewed guidelines on the management of superficial venous thrombosis (SVT) and emphasised the importance of performing duplex ultrasound in the examination, assessing clot location...
Cardiff Metropolitan University has announced it has secured a grant to “support an interdisciplinary collaboration of an innovative sterilising device for venous access ports (VAPs).” Existing VAPs tend to encourage the build-up of bacteria and fungus in the port, leading...
BTG has announced its finalised category I CPT codes, received from the US Centers for Medicare and Medicaid Services. The codes will be be effective from 1 January, 2018. The fee schedule details payments for conducting Varithena treatments in the...
Cardiff Metropolitan University has successfully secured funding to support an interdisciplinary collaboration arising from the Welsh Crucible programme that looks at the design and development of an innovative sterilising device for venous access ports (VAPs). The interdisciplinary research is a...
The US Centers for Medicare and Medicaid Services (CMS) has posted the 2018 Medicare Physician Fee Schedule (CMS-1678-F) and Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems (CMS-1678-FC). As part of the final rulings, healthcare providers will...

Nick Morrison

Nick Morrison chose venous medicine as he wanted a challenging career. Although he initially worried that he would become bored working in the venous field, his long and distinguished career since then is proof of the complexity and depth of...
Continuing work to develop an improved percutaneous valvuloplasty procedure “is promising”, said Johann Chris Ragg (Angioclinic Vein Centers, Berlin, Munich, Germany, and Zurich, Switzerland), as he updated delegates on the technique at the annual American College of Phlebology meeting...
Inferior vena cava (IVC) filters have been a highly controversial topic in the field of venous medicine due to the high rates of complications associated with their use, which eventually prompted a 2010 US Food and Drug Administration (FDA) advisory and declining...
Highlights: -MOCA and EVLA show similar overall pain scores and improvements in quality of life and clinical outcomes -First European advice on deep vein thrombosis published in European Heart Journal -Armando Mansilha: Chronic venous disease -Sophie Renton: Venous ulceration guidelines -Profile:...

Venous News 3 – November 2017

Highlights: -MOCA and EVLA show similar overall pain scores and improvements in quality of life and clinical outcomes -First European advice on deep vein thrombosis published in European Heart Journal -Armando Mansilha: Chronic venous disease -Sophie Renton: Venous ulceration guidelines -Profile:...
While comparative study data for venous stents are still lacking, results of a number of ongoing and planned venous stent trials will increase the options currently available to physicians and provide useful comparative data, explained Stephen Black (London, UK),...
Endovascular treatment of iliocaval and infrainguinal post-thrombotic venous obstruction results do not appear to be adversely affected by extension of the iliac vein stents into the femoral venous system, according to a US report in the Journal of Vascular...
Janssen Pharmaceuticals has announced that the FDA has approved the 10mg once-daily dose of rivaroxaban (Xarelto) for reducing the continued risk for recurrent venous thromboembolism (VTE) after completing at least six months of initial anticoagulation therapy. The approval follows a...
Inari Medical has announced that it has completed enrolment of its investigational device exemption (IDE) study. The FlowTriever Pulmonary Embolectomy Clinical Study (FLARE) study is designed to evaluate the safety and effectiveness of the FlowTriever Retrieval/Aspiration System for the...
Deep venous stenting has become increasingly used to treat patients with pathological obstruction of venous return in the femoro-iliocaval venous segment following the development of new dedicated venous stents. Patients treated range from those with an isolated non-thrombotic iliac vein lesion, to those...
Marianne De Maeseneer

Marianne De Maeseneer

Marianne De Maeseneer already wanted to become a doctor by the age of 12, with her imagination captured by the idea of working in developing countries. A “series of coincidences” led her towards vascular and venous medicine, in which...
The first comprehensive European advice on deep vein thrombosis was recently published in the European Heart Journal. The recommendations were produced by the European Society of Cardiology (ESC) Working Group on Aorta and Peripheral Vascular Diseases and Working Group...
The world’s largest randomised trial comparing three central venous access devices—peripherally inserted central catheters (PICCs), Hickman-type devices and chest wall ports—should provide definitive results in terms of their relative efficacy and cost-effectiveness, Jon Moss, Glasgow, UK, told CIRSE delegates. The...
Gerard Goh, Radiology, The Alfred Hospital, Melbourne, Australia, reported results from a comparative study of inferior vena cava (IVC) filters at CIRSE 2017 that examined the effectiveness, safety and complication rates of the Celect, Celect Platinum and ALN vena...
Data from the LAMA (Laser ablation versus mechanochemical ablation) trial indicate that mechanochemical ablation (MOCA) is significantly less painful than endovenous laser ablation (EVLA) during treatment of superficial venous incompetence, though there is no difference in pain between the...
There are two things you need to know about me. Firstly, I am a health psychologist, with a specialist interest in behaviour change, implementation, and impact. Secondly, through a series of deep vein thromboses (DVTs) beginning with a post-partum iliofemoral clot in 2008...
Emerging evidence suggests that the lymphatics play an important role in the early pathogenesis and progression of peripheral arterial and venous diseases, suggest John Rasmussen and Eva Sevick-Muraca, writing for Venous News.  Functioning peri-adventitial lymphatics are essential for reverse cholesterol transport by macrophages to...
Although the venous stent is still a young technology, it is already offering new and exciting opportunities to patients with deep venous occlusive disease. Venous News spoke to Manjit Gohel (Cambridge, UK) about how his experience in with deep venous stenting,...
ElastiMed has raised US$1 million from a strategic investor, existing investors—The Trendlines Group and Pix Vine Capital—new private investors, and the Israeli Innovation Authority. This represents the company's second round of funding, bringing total raises to US$2 million to...
Inferior vena cava (IVC) filters have long been a controversial topic, and some physicians have even called for a total moratorium on their implantation. Venous News spoke to John Kaufman (Portland, USA) at the 2017 Vascular Interventional Advances 2017...
A study has shown modified human factor X to be a safe and effective reversal agent for prevention and treatment of bleeding in patients taking factor Xa oral anticoagulants. This new therapeutic factor X was inspired by a snake...
Twelve-month results from the SENTRY trial evaluating the Sentry bioconvertible inferior vena cava (IVC) filter (Novate) have shown a 0% rate of symptomatic pulmonary embolism, no instances of device failure and a 96% rate of bioconversion. Presenting that data...
Spectranetics has recalled the Bridge occlusion catheter “due to the possibility of a blocked guidewire lumen in some device units”. Using affected catheters could lead to the incorrect positioning of the device and subsequent uncontrolled haemorrhage. Spectranetics’ Bridge occlusion balloon...
Highlights: -Five-year data find foam sclerotherapy to be less effective than thermoablation or stripping for varicose veins -Questions remain over venous leg symptoms despite SYM vein consensus -Manjit Gohel: Stent flexibility -Eva Sevick-Muraca: Lymphoedema -Profile: Marianne De Maeseneer https://venousnews.com/wp-content/uploads/sites/19/2017/09/Venous-News-2-low-res_USA.pdf

Venous News 2 – September 2017

Highlights: -Five-year data find foam sclerotherapy to be less effective than thermoablation or stripping for varicose veins -Questions remain over venous leg symptoms despite SYM vein consensus -Manjit Gohel: Stent flexibility -Eva Sevick-Muraca: Lymphoedema -Profile: Marianne De Maeseneer https://venousnews.com/wp-content/uploads/sites/19/2017/09/Venous-News-2-low-res.pdf  
ManaMed has introduced PlasmaFlow, the first US Food and Drug Administrator-approved portable and tubeless deep vein thrombosis (DVT) prevention device throughout the USA. "We at ManaMed are thrilled that our innovative PlasmaFlow DVT prevention device is available to help mitigate...
Medtronic is expanding its embolisation product portfolio with the launch of the Concerto 3D detachable coil system. The system was launched at the Cardiovascular and Interventional Radiological Society of Europe annual meeting (CIRSE; 16–20 September, Copenhagen, Denmark). The Concerto 3D...
InGeneron has announced the publication of results from an investigator initiated case series in chronic leg wounds in the Journal of the European Academy of Dermatology and Venereology. In the case series, InGeneron’s proprietary adipose-derived regenerative cell (ADRC) technology was...
Boston Scientific will distribute Veniti’s Vici venous stent under a limited global distribution agreement. The terms of the agreement and specific regions and countries involved have not been disclosed. Launched in 2014, the Vici venous stent has gained wide market...
Straub Medical has announced that the first patient has been enrolled in the P-MAX study at the Karolinen-Hospital Arnsberg, Germany.  The post-market clinical follow-up study to assess the safety and effectiveness of the AspirexS venous catheter in the treatment of deep vein thrombosis will enrol over 80 patients by...
Results from a Czech study indicate that 1470nm laser treatment of saphenous vein reflux with both radial single-ring and 2ring fibres results in clinical improvement of symptoms and comparable occlusion rates. That said, in the early postoperative period, 2ring laser...
At the 2017 European Venous Forum (29 June–1 July, Porto, Portugal), a presentation given by Eberhard Rabe (Bonn, Germany) questioned whether the SYM Vein Consensus clarified all aspects of venous symptoms. Speaking with Venous News, Rabe explains which questions still remain regarding venous leg symptoms...

VIDIO trial results published

The VIDIO study, led by Paul Gagne, Southern CT Vascular Center, Darien, USA, showed that intravenous ultrasound (IVUS) is more sensitive for assessing treatable iliofemoral vein stenosis compared with multiplanar venography and frequently leads to revised treatment plans and the potential for improved clinical outcome.  The...
The American College of Phlebology (ACP) board of directors has selected Dean Bender as the new executive director for the ACP and ACP Foundation.  Bender has more than 30 years in global business management and considerable experience in venous and lymphatic medicine. He has served as vice president of business...
Teleflex has announced a new three-year product category contract with Vizient for non-tunnelled central venous catheters. Vizient is the largest member-driven health care performance improvement company in the USA. The new agreement for non-tunnelled central venous catheters, which became effective...
Medtronic has completed the previously announced sale of a number of its businesses to Cardinal Health, including its Deep Vein Thrombosis (compression) division. The transaction was worth US$6.1 billion. The company has also sold its Patient Care and Nutritional Insufficiency...
Venous News caught up with Lars Rasmussen (Danish Vein Centres, Denmark) at the European Venous Forum (EVF; 29 June–1 July, Porto, Portugal) to hear about his five-year follow-up comparing endovenous radiofrequency ablation, laser ablation, foam sclerotherapy and surgical stripping...
Writing for Venous News, Paul Gagne (Darien, USA) notes that during the past decade, evaluation and treatment of iliac or common femoral vein obstructive disease have become more familiar and common. Based on the landmark work pioneered by Peter...
The first results from the GARFIELD-VTE (Global anticoagulant registry in the field—venous thromboembolism) were presented at the International Society on Thrombosis and Haemostasis Congress 2017 (8–13 July, Berlin, Germany) providing a contemporary picture of VTE management worldwide. GARFIELD-VTE is a...
At the European Venous Forum (EVF; 29 June–1 July, Porto, Portugal), Mattia Mirandola (Peschiera del Garda, Italy) presented his four-year experience of using ClariVein (Vascular Insights) for mechanochemical ablation of the saphenous vein. He shared his results with Venous...
Endovenous adhesive closure systems are a useful adjunct to thermal ablation treatment for varicose veins, but it is vital that the possible side-effects of such treatments are discussed openly with patients pre-procedurally, according to a presentation at the European...
The UK’s Information Commissioner’s Office (ICO) has found that the Royal Free National Health Service (NHS) Foundation Trust (London, UK) did not adhere to the UK’s Data Protection Act when it provided patient details to Google DeepMind. The Trust, a...
A presentation at the American Venous Forum (AVF; 14–17 February, New Orleans, USA) has attempted to shed light on what could be an underdiagnosed cause of pelvic pain caused by pelvic venous insufficiency—iliac vein compression. Ratnam K N Santoshi (Center...
A study presented at the American Venous Forum (AVF; 14–17 February, New Orleans, USA) suggests that secondary interventions for primary iliac vein stenting are “associated with good outcomes,” with a rate of 10.2% reported. Aiya Aboubakr (Mount Sinai Hospital, New...
Bio2 Medical has announced the results of the Angel Catheter pivotal study published in the Journal of Vascular and Interventional Radiology. The Angel Catheter met all safety endpoints and demonstrated a significant reduction in clinically significant and fatal pulmonary...
The US Food and Drug Administration (FDA) has accepted, for priority review, a supplemental new drug application (sNDA) for Janssen’s Xarelto (rivaroxaban), to include a 10mg once-daily dose for reducing the risk of venous thromboembolism (VTE) after at least...

Keith Poskitt

Coming from a non-medical background, Keith Poskitt is unable to pinpoint exactly how his interest in the field developed. At school, science and sports—rugby and cricket in particular—vied for his attention. Following a serious ankle injury at the age of...
The US Food and Drug Administration (FDA) has approved betrixaban (Bevyxxa, Portola), the first and only anticoagulant for hospital and extended duration prophylaxis (35 to 42 days) of venous thromboembolism (VTE) in adult patients hospitalised for an acute medical...
Researchers at North Carolina State University (Raleigh, USA) and the University of North Carolina at Chapel Hill (Chapel Hill, USA) have developed a new surgical tool that uses low-frequency intravascular ultrasound to break down blood clots that cause deep...
Public Health England (PHE) and the Royal Society for Public Health (RSPH) have published “Everyday Interactions”, a report which aims to support healthcare professionals to record and measure their public health impact.  The report and toolkit were developed in close...
The results of the ACCESS PTS trial have been presented at the Society for Vascular Medicine 28th Annual Scientific Sessions (14–17 June, New Orleans, USA). The study found chronic deep vein thrombosis (DVT) patients with post-thrombotic syndrome (PTS) can...
New evidence suggests that minimally invasive methods to ablate superficial venous reflux in patients with end-stage venous insufficiency are as effective as traditional open venous stripping. Chronic venous insufficiency affects approximately 2.5 million Americans, with up to 20% developing venous...
In this supplement: --Life post-ATTRACT: The new challenge of DVT treatment --The future of DVT intervention in Europe: what needs to happen next --"With careful patient selection and a patent popliteal vein, DVT treatment can be completed in less...
Kathleen Gibson, Bellevue, USA, presented the three-year results of the VeClose clinical trial at the recent Charing Cross Symposium. Gibson spoke to Venous News about the study and about how she interprets the three-year data.
Results from the OPTALYSE PE trial have been presented at the American Thoracic Society International Conference in Washington, DC, USA. The results show that pulmonary embolism (PE) can be treated effectively with EKOS (BTG) over a shorter period and...
Highlights: -ATTRACT results are “a springboard” for future pharmacomechanical thrombolysis research -Paul Gagne: Stenosis threshold -Peter Gloviczki: A look into the future -Profile: Keith Poskitt https://venousnews.com/wp-content/uploads/sites/19/2017/05/Venous-News-1-US_low-res.pdf
Highlights: -ATTRACT results are “a springboard” for future pharmacomechanical thrombolysis research -Paul Gagne: Stenosis threshold -Peter Gloviczki: A look into the future -Profile: Keith Poskitt https://venousnews.com/wp-content/uploads/sites/19/2017/05/Venous-News-1-EU_low-res-1.pdf
At the American Venous Forum meeting (14–17 February, New Orleans, USA), Johann Christof Ragg (Berlin/Zurich, Germany/Switzerland), presented on the concept of obtaining ultrasound proof of pre-reflux stages of venous insufficiency. Ragg spoke to Venous News about what light his...
Data from the randomised controlled ATTRACT trial revealed that the addition of catheter-based intervention to standard-of-care anticoagulation failed to significantly decrease the occurrence of post-thrombotic syndrome in patients who received this treatment strategy when compared with its occurrence in...
Three-year outcomes from the VeClose US pivotal clinical trial and one-year data from the WAVES study have been presented at the 2017 CX Symposium in London, UK. Both results were presented by Kathleen Gibson (Bellevue, USA). The new data...
Isobar Compression has been awarded a research contract from the Small Business Research Initiative (SBRI) for Healthcare, to assist in a feasibly study in primary care for the treatment of venous leg ulcers. The research contract was awarded by SBRI...
Bluegrass Vascular Technologies has enrolled over one third of its patients in the company's post-market SAVE (Surfacer System to Facilitate Access in Venous Occlusions) clinical study. The SAVE study is an international, prospective, multicentre clinical follow-up study designed to...
Research published in Phlebology has indicated that the 2013 UK varicose veins clinical guidelines have led to “a considerable increase” in leg ulcer patient referrals, although many patients are still not being referred early enough, the authors of the paper...
Inari Medical, a venture capital backed medical device company focused on the interventional treatment of venous thrombus, has announced the treatment of the first patient with its ClotTriever thrombectomy system.  The system received 510(k) marketing clearance from the US Food and...
Further evidence has been found by researchers at the UK’s University of Leicester and University of Bristol to suggest statins could "significantly reduce" the occurrence of blood clotting in certain parts of the body. The research team analysed several studies...
Compression therapy is the mainstay of treatment for the symptoms of chronic venous insufficiency (CVI). CVI is treated with compression stockings or multilayer bandaging. However, as most compression stockings are supplied in standard sizes, they frequently failed to deliver...
The use of dedicated nitinol venous stents across the inguinal ligament shows “good outcomes” in terms of patency but reinterventions may be required, according to Prakash Saha, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London,...
Most existing surgical options for symptomatic deep venous insufficiency (DVI) with venous stasis ulcers either fail or provide limited success. Many surgeons consider operating on large veins such as the common femoral vein to be foolhardy—something new is required,...
A Canadian-led international research team has found that the blood thinner rivaroxaban is as safe as aspirin, and more effective at preventing recurrence of life-threatening blood clots in the legs and lungs, according to a study published in the...
In a new study presented at the American College of Cardiology 66th Annual Scientific Session, researchers from the Perelman School of Medicine at the University of Pennsylvania have found that the utilisation rates of these potentially life-saving medications are low, particularly in...
Unfors RaySafe has introduced the RaySafe i3, to its suite of real-time dosimetry products, at the European Society of Radiology in Vienna.   The RaySafe Real-Time Dosimetry solution, introduced in 2012, helps physicians and clinical staff visualise X-ray exposure in real...
The use of computerised clinical decision support systems among surgical patients are associated with a significant increase in the proportion of patients with adequately ordered treatment to prevent blood clots, and a significant decrease in the risk of developing...
CorVascular has entered into a distribution agreement with Novarix. The IV-eye, developed and manufactured in the UK by Novarix, is a near infrared (NIR) vein imaging device designed to aid healthcare professionals in finding suitable peripheral veins for both cannulation...
Nobilis Health has closed its previously announced acquisition of Hamilton Vein Center. “Hamilton Vein Center not only increases our in-network patient volume mix to over 60%, but its six facilities enhance our network of physicians, allowing Nobilis to generate additional...
Data from the randomised controlled ATTRACT trial revealed that the addition of catheter-based intervention to standard-of-care anticoagulation failed to significantly decrease the occurrence of post-thrombotic syndrome in patients who received this treatment strategy when compared to its occurence in...
The pivotal VeClose trial is investigating the performance of the VenaSeal cyanoacrylate-based adhesive (Medtronic) for vein closure. At LINC 2017, Vascular News caught up with Raghu Kolluri (OhioHealth Vascular Institute, Columbus, USA) who explained his experience with the system...
Primary chronic venous disease is poorly documented in paediatric patients, excluding those diagnosed with Klippel-Trenaunay syndrome (KTS) and post-thrombotic syndrome, writes Dawn Coleman. The Bochum Study previously studied 136 children (aged 10–12 years) longitudinally out to 31 years and...
Having received CE mark approval in July and Health Canada approval in August of last year, FlowAid Medical Technologies has now received US Food and Drug Administration (FDA) clearance for its FA100 SCCD (Sequential Continuous Contraction Device) for the following indications: increase of...
In this clinical study the one-year results of the endovenous laser therapy (ELT) application of 1,940nm laser (Vela XL, Boston Scientific) with respect to feasibility, efficacy and safety are reported. Anna Esipova and colleagues investigated the performance of longer...
The question is often asked: is intravascular ultrasound (IVUS) necessary in a deep venous practice? Stephen Black writes that it was certainly a question that he had asked when initially building his practice. The answer predominantly seemed to be that...
In this interview, Vascular News speaks to Prakash Saha, King’s College Hospital, London, UK, about the growth of deep venous treatment and how the field can best address the ever-growing list of challenges. What are the challenges you face...
Following Health Canada regulatory approval, BTG is to launch its polidocanol injectable foam (Varithena), a drug/device combination product used to treat varicose veins, in Canada. The product is intended for use in adults with clinically significant venous reflux as...
Two-year outcomes of the VeClose pivotal trial have been reported, showing a 94.3% closure rate and “continued non-inferiority results to radiofrequency ablation” when using the VenaSeal cyanoacrylate embolic adhesive closure system (Medtronic). The data were presented by Raghu Kolluri,...
A Dutch study of greater saphenous vein insufficiency patients has found that mechanochemical ablation (MOCA; ClariVein, Vascular Insights) is an effective and safe treatment with low postoperative pain and fast recovery. Speaking at the 2016 VEITHsymposium (15–19 November, New...
Fresh data from a Turkish CAPE (cyanoacrylate adhesive perforator embolisation) trial indicate that the method is “as effective as endovenous thermoablative techniques, without the risks of potential inadvertent thermal lesions” for treating incompetent perforating veins. The presentation was given...
Highlights: -Animal experiments raise possibility of wireless vascular flow monitoring -Global variations in abdominal aortic aneurysm care revealed -Jerry Fortuna: Battlefield trauma -Stephen Black: IVUS -Profile: R Clement Darling III http://venousnews.com/wp-content/uploads/sites/19/2017/01/73-VN-US-v2.pdf
Highlights: -Animal experiments raise possibility of wireless vascular flow monitoring -Global variations in abdominal aortic aneurysm care revealed -Jerry Fortuna: Battlefield trauma -Stephen Black: IVUS -Profile: R Clement Darling III http://venousnews.com/wp-content/uploads/sites/19/2017/01/73-VN-v2.pdf
Robert Califf is to step down as US Food and Drug Administration (FDA) commissioner upon the inauguration of Donald Trump as US President on 20 January 2017. Democrat Califf, who was appointed to the post in September 2016 by...
The first Hong Kong-based patients diagnosed with pulmonary embolism have been treated using the newly available BTG EKOS system. The EKOS system includes an ultrasonic device that uses acoustic pulses to quickly and safely dissolve blood clots and restore...
Teleflex’ Arrow Vascular positioning system (VPS) Rhythm device with optional TipTracker technology has been issued 510(k) clearance from the US Food and Drug Administration (FDA) to commercialise the device in the USA. According to a company release, the Arrow VPS...
Abbott has now completed the acquisition of St Jude Medical. The Abbott press release announcing the completion of the acquisition said, “The transaction provides Abbott with expanded opportunities for future growth and is an important part of the company's...
Gerard O’Sullivan, Department of Radiology, University Hospital Galway, Ireland, presented the results of the VIVO-EU prospective study of the Zilver Vena venous stent (Cook Medical) in the treatment of symptomatic iliofemoral outflow obstruction at the Cardiovascular and Interventional Radiological...

US FDA bans powdered gloves

The US Food and Drug Administration (FDA) has issued a final rule to ban powdered surgical gloves, patient examination gloves and the absorbable powder used to lubricate surgical gloves. Citing associations with serious adverse events—including allergic reactions, lung and airway...
The UK’s National Institute for Health and Care Excellence (NICE) has announced its participation in the US Food and Drug Administration (FDA)’s Payer Communication Taskforce. This programme aims to accelerate US patient access to new technologies by gathering evidence...
The first patient has been enrolled in Daiichi Sankyo’s EMIT-AF/VTE (Edoxaban Management in Diagnostic and Therapeutic Procedures) study. This registry will collect real-world clinical data on the use of once-daily edoxaban (Lixiana) with regard to diagnostic and interventional procedures...
LimFlow has received CE mark for its fully percutaneous LimFlow system designed for venous arterialisation of the lower limbs in end-stage patients at risk of limb amputation for critical limb ischaemia. The LimFlow system is a percutaneous therapy for patients...
Cook Medical has completed enrolment in the first clinical study of an iliofemoral venous stent conducted in the USA under an FDA-approved investigational device exemption. The VIVO clinical study is a prospective, non-randomised, multicentre study intended to evaluate the...
biolitec has announced the development of a “revolutionary, versatile and compact laser for medical application,” with the Leonardo Mini—“a space-saving, efficient, and versatile multi-functional laser,” a company press release says. The device, weighing only 900g, is available in two designs;...
Highlights: -EVAR 1 trial 15-year follow-up published: Lifelong surveillance of EVAR and prompt reintervention are paramount -IVUS may be a more accurate method than venography for assessing lesion severity and proper venous stent size -Fabio Verzini: EVAR devices -Armando Mansilha:...
Highlights: -EVAR 1 trial 15-year follow-up published: Lifelong surveillance of EVAR and prompt reintervention are paramount -IVUS may be a more accurate method than venography for assessing lesion severity and proper venous stent size -Fabio Verzini: EVAR devices -Armando Mansilha:...
These are exciting times for physicians involved in the management of venous disease. There have been important advances in basic scientific research and crucial developments in venous imaging and diagnostics. Most importantly, however, writes Manj Gohel, physicians now have...
The results of the VIRTUS feasibility study—analysing the performance of the Vici venous stent system (Veniti) in achieving patency of venous lesions up to 12 months—have recently been released, indicating that intravascular ultrasound (IVUS) may be a more accurate...
Jens Eldrup-Jorgensen has been named the new medical director of the Society for Vascular Surgery Patient Safety Organization (SVS PSO). He will replace Jack Cronenwett, who has served as medical director since 2011. The SVS PSO is a part...
The Vascular Society of Great Britain and Ireland celebrates its golden anniversary in Manchester later this month. It was initially founded by Sol Cohen as the Vascular Surgical Society in 1966 with the first two meetings held in London...
Fresh data from the VIRTUS feasibility study presented at the Vascular Interventional Advances (VIVA) annual conference 2016 (18–22 September, Las Vegas, USA) suggest that venography may underestimate the severity of venous lesions and that intravascular ultrasound (IVUS) may be...
The goal of management of venous thromboembolic disease is to prevent thrombus extension or embolisation and to prevent early and late episodes of recurrence. Armando Mansilha, Porto, Portugal, explains how our approach has changed and what obstacles still face...
Janssen Pharmaceuticals and its development partner, Bayer, announced on 23 October 2016 results of two new real-world studies confirming the positive benefit-risk profile of rivaroxaban (Xarelto) in treating venous thromboembolism, and reducing the risk of recurrence. One study showed that...
Superficial vein thrombosis (SVT) is a common disease affecting 3–11% of the general population, while in patients with varicose veins the incidence of SVT increases to as much as 60%. The prevalence of SVT appears to be two-fold higher...
Lymphoedema is a chronic, progressive condition which can often be debilitating. It is caused by a deficiency or failure of the lymphatic system. Due to its chronic nature, lymphoedema requires ongoing treatment to manage and control the swelling. It...
Ovsep Mandzhikian, Moscow, Russia, reports on his centre’s recent experience of endothermal heat-induced thrombosis following treatment with endovenous laser and radial fibres, suggesting that complications following the treatment are rare and asymptomatic. Our multicentre observational study summarises the experience of...
Veniti has closed on US$25m in Series D equity financing from Boston Scientific Corporation. The funds will allow Veniti to complete the VIRTUS trial and regulatory filing for the Vici Venous Stent system. The trial is being performed under...
Ash Verma, Clearwater, USA, writes how last year, he happened upon a routine case that struck him as both totally unremarkable and absolutely extraordinary. A 69-year-old female patient presented with one week of swelling and pain in her left...
In this special feature, Vascular News takes a look at occupational radiation—one of the most pressing concerns for vascular and endovascular professionals—speaking to several experts about the dangers of, and strategies to minimise exposure to, radiation in the operating room. http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/09/Vascular-News-71-Radiation-single-pages.pdf
Highlights: -Iliac branch device results show value of internal iliac artery revascularisation -Absorb bioresorbable scaffold yields 96% primary patency and freedom from reintervention below the knee at 12 months – In the spotlight: Radiation danger -Ragg: Biomatrix sclerofoam -Profile:...
Highlights: -Iliac branch device results show value of internal iliac artery revascularisation -Absorb bioresorbable scaffold yields 96% primary patency and freedom from reintervention below the knee at 12 months - In the spotlight: Radiation danger -Ragg: Biomatrix sclerofoam -Profile:...
Bluegrass Vascular Technologies has received CE mark approval and is launching limited commercial sale of its Surfacer Inside-Out access catheter system. The Surfacer system is indicated for obtaining central venous access to facilitate catheter insertion into the central venous...
A post-market evaluation of the VenaSeal closure system (Medtronic) has found that, at one month, 100% of treated veins remained closed, quality of life scores improved significantly, and return to work and normal activity times were short. The data...
FlowAid Medical Technologies has received CE mark approval for its FA100 SCCD sequential contraction compression device. According to a press release, the FA100 SCCD was designed with the patient in mind, intended to offer an easy to use system, allowing...
Christopher G Carsten III, Greenville Health System, Greenville, SC, USA Radiation safety practices have made tremendous advances since the discovery of Roentgen’s X-rays over 120 years ago. The sacrifices of early practitioners have led to the knowledge that now allows...
The US Food and Drug Administration (FDA) has released a draft guidance document entitled “Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices”. According to an email from the consumer watchdog, the document is intended to clarify “how...
The National Institute for Health and Care Excellence (NICE) has recently issued approval via Interventional Procedure Guidance IPG557 for endovenous mechanochemical ablation for the treatment of varicose veins in the UK. The NICE guidelines provide evidence-based guidance and advice on a range...
BTG has announced that the US Food and Drug Administration (FDA) has approved an extension of the post-activation shelf life of Varithena (polidocanol injectable foam) 1% to 30 days from seven. The announcement was made on 6 July 2016. “This approval...
6 July 2016 Venous Stenting Training Day Guys and St Thomas' Hospital, London, UK http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/06/Final-Flyer-stent-course-SB-2016.pdf  
The delivery and exploration of new technology is required to reduce harmful levels of radiation during endovascular procedures, according to Edward Diethrich, a veteran cardiovascular surgeon with first-hand experience of the damage that such exposure can cause. Following many years’...
Physicians have now treated over 1,000 patients with the Vici Venous Stent. The product received CE mark in October 2013 and was first implanted in January 2014. Subsequently, it has been launched in 13 countries worldwide. Veniti says that...
Therapies in deep venous thrombosis (DVT) have been slow to advance over the past 50 years. Recently, growing awareness and improvements in tools and techniques have piqued interest in venous disease. The ATTRACT trial will try to answer the...
Highlights: -CX acknowledges “huge debt” owed to endovascular pioneers affected by radiation -Audience voting finds a place for false lumen embolisation in chronic type B dissections -Martin Bjӧrck: Iliac artery screening -Ian Franklin: Non-thrombotic iliac lesions -Profile: Wesley Moore http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/06/70-Vascular-News_US.pdf
Highlights: -CX acknowledges “huge debt” owed to endovascular pioneers affected by radiation -Audience voting finds a place for false lumen embolisation in chronic type B dissections -Martin Bjӧrck: Iliac artery screening -Ian Franklin: Non-thrombotic iliac lesions -Profile: Wesley Moore http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/06/Vascular-News-70-EU-08.pdf
The US Food and Drug Administration (FDA) has finalised its efforts to streamline the “compassionate use” process, used by physicians to access investigational drugs and biologics for patients with limited treatment options. A statement from Robert Califf, the deputy...
A new bill introduced to the US Senate by Senator Dan Coats seeks to address the gap between the US Food and Drug Administration (FDA)’s priority review process for breakthrough medical devices, and the Centers for Medical and Medicare...
The Netherlands presidency of the European Council and representatives of the European Parliament have reached a political agreement on two draft regulations for medical devices. The new regulations are aimed at ensuring that medical devices and in vitro diagnostic...
At the 2016 Charing Cross Symposium (26–29 April, London, UK) and the International Vein Congress (28–30 April, Miami, USA) Medtronic unveiled clinical data for the VenaSeal closure system demonstrating consistent long-term durability and improved quality of life in patients with venous...
Since its introduction in the late 80s, endovascular therapy has become increasingly widespread and important. A mini-symposium held at the 2016 Charing Cross Symposium (26–29 April, London, UK), brought to the fore the radiation damage that has occurred to...
In a study comparing multiplanar venography to intravascular ultrasound (IVUS) for diagnosing common or external iliac and common femoral vein stenosis, IVUS imaging was found to change both the treatment plan in 60/100 patients and the number of stents...
Two 2016 Charing Cross Symposium (CX 2016; 26–29 April, London, UK) presentations in the Venous Challenges Main Programme session have demonstrated the value of dedicated venous stents, with interim results from two studies in patients with symptomatic iliofemoral venous...
Now that non-thrombotic iliac vein lesions (NIVLs) are more frequently recognised on modern imaging modalities, they are beginning to trigger a paradigm shift in standard vein work whereby there is now increasing emphasis on making sure that these patients...
The first patient suffering from post-thrombotic syndrome associated with venous outflow obstruction has been treated with the VICI VERTO VENOUS STENT system. This stent delivery system allows the physician to deploy a venous stent beginning at the peripheral end...
A study conducted at St Thomas’ Hospital, London, UK, indicates that the VeinCLEAR catheter (RF Medical) produces good results when used in radiofrequency ablation in the treatment of lower extremity superficial venous insufficiency. The study team, led by Adam...
The Surfacer Inside-Out access catheter system (Bluegrass Vascular Technologies) has been successfully used in its first clinical case. The patient in question was facing life-threatening complications from end-stage renal disease.The procedure was performed under Germany’s "compassionate use" program, which...

“EVRF (F Care Systems) saphenous ablation is a safe and painless procedure for the treatment of the greater saphenous vein and/or small saphenous vein,” according to recently released data. The authors, led by Attila Szabo, VP-Med Health and Education Centre, Budapest, Hungary, write that “high patient acceptance and minimal postoperative discomfort allows a quick return to work and normal life for patients.”

EVRF is a monopolar radiofrequency ablation system for endothermal treatment of small, midsize and large veins. “Endovenous procedures are far less invasive than surgery and have lower complication rates,” the authors write. “The procedure is well tolerated by the patients, and it produces good cosmetic results. Excellent clinical results are seen at four to five years, and the long-term efficacy of the procedure in now known with 10 years of experience.”


Szabo and colleagues evaluated the effectiveness of EVRF treatment and analysed the three-year results of using the device for endovenous radiofrequency ablation and spider vein treatments from July 2011 to March 2015 to treat 751 saphenous reflux and varicosity patients.


Radiofrequency ablation using the EVRF CR45i catheter was performed on 751 limbs (628 greater saphenous vein, 102 small saphenous vein and 21 for both). Complete occlusion was found in 743 of 751 cases (99%) at one month. At one-year follow-up, 15 of 530 patients showed recanalisation longer than 5cm (97.2% one-year occlusion) without clinical symptoms. The three-year occlusion rate was 96.6% (two of 59 patients had an open vein segment). At one-year follow-up the investigators evaluated the postoperative pain reported by the patients on a visual analogue scale (2.4 preoperatively, 1.2, 0.4 and 0.1 at one week, one month and one year postoperatively, respectively) and Venous Clinical Severity Scores (7.7, 3.9 and 1.8 before surgery, at one month and at one year, respectively). The average patient satisfaction was 99% at one year. There were no cases of deep vein thrombosis, skin burns, neuritis or bleeding. “Minimal” bruising was observed at the treatment site of the tributaries in some cases and four patients had mild inflammation which was treated conventionally.


For smaller veins, more than 5,000 treatment sessions for teleangiectasias and spider veins on the face and lower limbs were completed. The authors used radiofrequency treatment or combined the treatment with liquid sclerotherapy. Facial recovery rate was 100% and lower limb recovery rate was 82% on average. The treatments were “well tolerated—although the pain level always depends on the patients’ current psychic status—and the patient satisfaction rate was high,” the authors report.


Szabo and colleagues suggest that “EVRF is appropriate for the treatment of teleangiectasias, reticular veins with the hand piece and K3i or K6i needles (face or lower leg), small varicose veins or tributaries 2–5mm with the hand catheters and for saphenous truncs and perforators 4–15mm in diameter with the CR45i catheter.”


“The procedure, under local tumescent anaesthesia, is simple and the disposable devices are easy to use. The EVRF hand piece with K3i and K6i needles proved to be useful in teleangiectasia treatment, with excellent results,” Szabo et al conclude. “This radiofrequency procedure is also suitable for combination with liquid or foam sclerotherapy.”

Boehringer Ingelheim has announced the enrolment of the first patient in RE-COVERY DVT/PE, a global observational study on the management of deep vein thrombosis (DVT) and pulmonary embolism (PE). “Large pivotal randomised trials have revolutionised our strategies to manage and...
The US Food and Drug Administration has announced a proposal to ban most powdered gloves in the USA. While use of these gloves is decreasing, they pose an unreasonable and substantial risk of illness or injury to health care...
Highlights: -Tackling the challenges in the vascular and endovascular arena -CX Venous Workshop -CX Vascular Access course -CX Edited Live Cases -CX ilegx Collaboration Day -CX Acute Stroke Challenges Programme -Summary of Vascular News and Interventional News profiles 2015 http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/03/VNCharingCross2016US_lowres.pdf
Highlights: -Tackling the challenges in the vascular and endovascular arena -CX Venous Workshop -CX Vascular Access course -CX Edited Live Cases -CX ilegx Collaboration Day -CX Acute Stroke Challenges Programme -Summary of Vascular News and Interventional News profiles 2015 http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/03/VNCharingCross2016EU_lowres.pdf
Hybrid operative thrombectomy achieves complete thrombus resolution in one operating room trip which results in reduced length of stay, bleeding complications and transfusions when compared with percutaneous treatments that use thrombolytic therapy. This can be achieved without sacrificing successful...
A few months ago a discussion on the LinkedIn page of the American College of Phlebology caught my attention: “Medicare: maximum four endovenous laser 
therapies per lifetime?” In Belgium we can use one radiofrequency catheter or endovenous laser ablation fibre...
According to the World Health Organization, around 300 million people are affected by the pathological oedema of limbs. Lymphoedema is caused by partial or total obstruction of lymphatic collectors as a consequence of skin and deep soft tissue inflammation,...
Saphenous pulsation is the cyclical impulse of antegrade flow observed on colour duplex ultrasound after prolonged standing. It is a common observation in patients with saphenous reflux and is detected in the upper part of the great saphenous vein,...
AngioDynamics has signed an agreement with Merz North America, a US affiliate of the global Merz Pharma Group, to serve as the exclusive distributor of Asclera (polidocanol) injection within the US vein market. Asclera is approved for the treatment of uncomplicated spider and uncomplicated...
At the 2016 Leipzig Interventional Course meeting (LINC; 26–29 January, Leipzig, Germany), Michael R Jaff, Boston, USA, discussed the challenges facing intervention for deep vein thrombosis and pulmonary embolism, and when using an interventional approach may be preferable. “When you...
The US Food and Drug Administration (FDA) has confirmed the appointment of Robert Califf as its 22nd commissioner, following a US Senate vote of 88 to 4 in his favour. Califf was nominated to replace previous commissioner, Margeret A Hamburg, by...
ArtVentive Medical has announced enrolment in the ongoing OCCLUDE post-market surveillance study. This study aims to further the use of the EOS endoluminal occlusion system for the treatment of venous and arterial cases in which precise placement and immediate,...
Highlights: -Neuromonitoring changes trigger protocol against spinal cord ischaemia during TEVAR -New European industry code: Sponsorship of physicians to attend congresses to be done via healthcare organisations -In the spotlight: Atherectomy -Raphaël Coscas: Vascular access -Profile: Jonathan Beard http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/69-Vascular-News_US.pdf
Huntleigh has launched the Dopplex DMX digital vascular Doppler. According to a company release, this Doppler combines audio clarity and a visual representation of waveforms with high performance probe sensitivity.
Cook Medical has initiated a voluntary recall of 360 specific lots of single lumen central venous catheters and pressure monitoring sets and trays due to catheter tip fracture and/or separation. Globally, 17,827 devices are subject to this recall.
The kit comprises the company's DMX Doppler, probes and accessories to aid the vascular, diabetic or lymphatic specialist with the assessment of arterial disease and neuropathy.
Highlights: -Neuromonitoring changes trigger protocol against spinal cord ischaemia during TEVAR -New European industry code: Sponsorship of physicians to attend congresses to be done via healthcare organisations -In the spotlight: Atherectomy -Raphaël Coscas: Vascular access -Profile: Jonathan Beard http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/69-Vascular-News_EU.pdf  
Rick De Graaf, Department of Radiology, Maastricht University Medical Centre, Maastricht, The Netherlands, presented the results of the first comparative study of four dedicated stents for the venous system at the VEITHsymposium (17–20 November 2015, New York, USA). De...
Researchers have activated the first 10 medical sites and enrolled the first nine patients in a study that will determine the safety and effectiveness of inferior vena cava filters, small, cage-like devices implanted to prevent life-threatening blood clots from...
Bristol-Myers Squibb and Pfizer have announced results from a post-hoc early time course subanalysis of the phase 3 AMPLIFY (Apixaban for the initial management of pulmonary embolism and deep vein thrombosis as first-line therapy) trial. The subanalysis demonstrated Eliquis (apixaban) was comparable to...
Bayer and its development partner Janssen Pharmaceuticals presented results from two real world studies—the non-interventional XALIA study in patients with deep vein thrombosis (DVT) and a study looking at patients with cancer-associated thrombosis on 8 December 2015. Results from...
The European Diagnostics Manufacturers Association (EDMA) and the European Medical Technology Industry (Eucomed) have approved a new joint code of conduct that stipulates that, after 31 December 2017, industry should no longer provide direct “financial or in kind support”...
Highlights: -IN.PACT SFA two-year results "have potential to drive paradigm shift" in femoropopliteal lesion treatment -PERICLES study helps bring chimney technique "out of the shadows" -Endologix and TriVascular announce merger -Jeffrey P Carpenter: Protection devices -Peter H Lin: Thrombolysis...
Highlights: -IN.PACT SFA two-year results "have potential to drive paradigm shift" in femoropopliteal lesion treatment -PERICLES study helps bring chimney technique "out of the shadows" -Endologix and TriVascular announce merger -Jeffrey P Carpenter: Protection devices -Peter H Lin: Thrombolysis...
By Athanasios D Giannoukas Today, venous stenting plays an important role in the treatment of deep venous pathologies. The current indications for its use include acute iliofemoral thrombosis after catheter-directed or pharmacomechanical thrombolysis to resolve residual iliac stenosis, May-Thurner syndrome and...
According to new a study published in PLOS Medicine, a new clinical model can help predict the risk of venous thromboembolism (VTE) among patients with a leg case, enabling doctors to identify high risk cases. Using data from three large cohorts,...
Medtronic’s VenaSeal closure system has been granted pre-market approval (PMA) from the US Food and Drug Administration (FDA) for the treatment of symptomatic venous reflux. This minimally invasive procedure is the first and only non-tumescent, non-thermal, non-sclerosant procedure approved for...
Peter H Lin   Pulmonary embolism in children is a potentially lethal condition and yet is a vastly understudied arena. Autopsy studies show a higher prevalence of pulmonary embolism compared to medical database registries suggesting that this condition is often clinically...
Highlights: -"Working with radiation is like keeping a pet tiger in your living room" -Wearable exercise tracker improves intermittent claudication symptoms at six months -Endovascular revolution in the aorta: 25 years of a landmark case -Profile: Sebastian Debus -Rabih...
Highlights: -"Working with radiation is like keeping a pet tiger in your living room" -Wearable exercise tracker improves intermittent claudication symptoms at six months -Endovascular revolution in the aorta: 25 years of a landmark case -Profile: Sebastian Debus -Rabih...
At procedure, Zilver Vena stent placement resulted in a more than two-fold improvement in the vessel minimum lumen diameter. Based on available follow-up data, stent placement has corresponded to improved clinical symptoms.
The City University of New York (CUNY), Lawrence Livermore National Laboratory, and Near Infrared Imaging, have released the “Vein-Eye” camera. The Vein-Eye provides enhanced visualisation of veins when drawing blood or placing IVs in a patient’s arm or hand....
By Johann Chris Ragg  Patients with saphenous insufficiency can undergo valve zone shaping instead of destructive methods by surgical removal or endovenous closure, says Johann Chris Ragg. He presented the new vein restoring modality at the European Venous Forum (EVF;...
Dedicated venous stents can be effectively used to relieve outflow obstruction at one year following thrombotic disease in both the acute and chronic setting, according to the prize-winning research presented at the European Venous Forum (EVF; 2–4 July, Saint...
The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.NICE has issued its final recommendation...
The study concluded that treatment with ultrasound-facilitated catheter-directed low-dose thrombolysis for acute pulmonary embolism improves right heart function, reduces blood clot size, and decreases pulmonary hypertension in patients with intermediate to high risk pulmonary embolism.
The first patient has been enrolled in ETNA-AF-Europe (Edoxaban treatment in routine clinical practice – atrial fibrillation – Europe), and ETNA-VTE-Europe (Edoxaban treatment in routine clinical practice – venous thromboembolism – Europe) has commenced. Daiichi Sankyo’s European ETNA registries are...
Results of the landmark CATCH (Comparison of Acute Treatments in Cancer Haemostasis) study were published in The Journal of American Medical Association (JAMA), comparing innohep (tinzaparin), a low-molecular weight heparin (LMWH), with warfarin in patients with cancer-associated thrombosis. In the study, sponsored by...
BTG announced on 6 August 2015 that Health Canada has issued a notice of compliance approving polidocanol injectable foam (Varithena, BTG) for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous...
By Samuel Money Open vena caval surgery is rare. It is mainly performed for oncological indications when the inferior vena cava is involved by an adjacent tumour. One of the most common malignancies that affect the inferior vena cava is...
Ian Franklin, a member of the CX Programme Organising Board and director of the CX Venous Workshop, speaks about new technologies for the treatment of varicose veins and about how deep venous interventions have been incorporated to the CX...
After the European launch in April 2015, Biolas has introduced the VariClose Vein Sealing Systems in the European market for the treatment of varicose veins.
NICE has issued a Final Appraisal Determination (FAD) for Lixiana (edoxaban) for the treatment and prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults.
BioGlue is now indicated for adhesion and support of haemostasis for aortotomy closure sites, suture/anastomosis sites (including aortic dissection and anastomosis sites with a prosthetic graft), and suture sites on the heart.
The 12-month closure rates for Medtronic's VenaSeal closure system are comparable to those achieved using radiofrequency ablation.
Twelve-month results from the VeClose trial have demonstrated cyanoacrylate adhesive (CAE) is non-inferior to radiofrequency ablation (RFA) for the treatment of incompetent great saphenous veins.
Highlights: -One-year IMPROVE data suggest benefit of EVAR in ruptured aneurysms -New Eluvia drug-eluting stent shows 94.4% primary patency rate at nine months -Michael Dake: Arch branded device -Andrew Holden: Bioresorbable stents -Profile: Janet Powell http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/66-Vascular-News-USA.pdf  
Highlights: -One-year IMPROVE data suggest benefit of EVAR in ruptured aneurysms -New Eluvia drug-eluting stent shows 94.4% primary patency rate at nine months -Michael Dake: Arch branded device -Andrew Holden: Bioresorbable stents -Profile: Janet Powell http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/66-Vascular-News-EU.pdf  
Jan Heyligers and Patrick Vriens, Tilburg, The Netherlands, write about a technique using the great saphenous vein for the reconstruction of an infected aorta. The technique, defined as a “see one, do one” procedure, was presented at the Charing...
The decision provides supplemental reimbursement to US hospitals for the new medical device with the potential to improve outcomes for patients undergoing a percutaneous transthoracic lung biopsy.
Bristol-Myers Squibb and Pfizer have announced that the National Institute for Health and Care Excellence (NICE) has published final guidance recommending the use of Eliquis (apixaban) as an option for the treatment of deep vein thrombosis (DVT) and pulmonary...
As part of a 90-day implementation plan, the NHS now has three months for apixaban to be made available to patients in England and Wales whose doctors believe it is a clinically appropriate treatment for them.
This video tells the story of one of the world’s most prominent heart surgeons, Edward Diethrich, and the career-altering health issues he has faced as a result of chronic, low-level exposure to ionising radiation through his work. https://youtu.be/rXgt0bF3GJM
Highlights: -Discussion of controversies tops Charing Cross 2015 agenda -CX Venous Workshop -CX Live Peripheral Arterial Cases -CX Edited Live Cases -CX ilegx Collaboration Day -Summary of Vascular News and Interventional News profiles 2014 http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/CX-Vascular-News-2015-US_low-res.pdf
The second day of the CX Venous Workshop was held yesterday on the Upper Level of the Gallery, rounding off a busy week in which more than 950 people visited over the two days—a new record for the Workshop....
Yesterday saw the beginning of the two-day CX Venous Workshop, in which delegates can enjoy expert demonstrations of a selection of the most interesting and important phlebological technologies currently in use. Now in its seventh year, the event continues...
Observational studies show a sharp increase in the placement of inferior vena cava filters over the past three decades, including their use as add-on therapy to anticoagulant therapy in patients presenting with a blood clot.
Daiichi Sankyo has announced that Swissmedic, the regulatory authority of Switzerland, has granted approval of Lixiana (edoxaban), an oral, once-daily selective factor Xa inhibitor, for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. Simultaneously,...
Early data from a multicentre, single-arm study that set out to evaluate the safety and effectiveness of a novel approach to inferior vena cava filtration using the VenaTech convertible filter (B Braun Interventional Systems) suggest that the use of...
Intrinsic Imaging has been awarded a clinical trial to study an interventional medical device designed for the prevention of pulmonary emboli. Throughout this trial, Intrinsic Imaging will provide imaging core lab services including, but not limited to, protocol and charter...
Highlights: -Discussion of controversies tops Charing Cross 2015 agenda -CX Venous Workshop -CX Live Peripheral Arterial Cases -CX Edited Live Cases -CX ilegx Collaboration Day -Summary of Vascular News and Interventional News profiles 2014 http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/CX-Vascular-News-2015-EU_low-res.pdf
The Medtronic VenaSeal system is intended for patients with symptomatic superficial varicose veins of the legs.
biolas has announced the launch of its VariClose vein sealing systems in Europe. VariClose is a new technique by which an incompetent saphenous vein is sealed through embolization. biolas says that the procedure is simpler and more successful than older...
Medtronic announced today that a previously communicated global voluntary recall to address an issue with certain lots of its Trellis-6 and Trellis-8 peripheral infusion systems has now been classified as a Class 1 recall by the US Food and...
The US Food and Drug Administration (FDA) has approved Daiichi Sankyo’s Savaysa (edoxaban), an oral, once-daily selective factor Xa inhibitor, to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. In ENGAGE AF-TIMI 48, Savaysa...
Highlights: -Publishing individual outcome data way make physicians risk averse -Early results suggest Lithoplasty is effective in the treatment of calcified lesions -SPACE 2 cartoid study is halted -Juan Perodi: A humble patient -Rocha-Singh: DEBs below-the-knee -Profile: Jean-Baptiste Ricco http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/65-Vascular-News-US_low-res-1.pdf
Highlights: -Publishing individual outcome data way make physicians risk averse -Early results suggest Lithoplasty is effective in the treatment of calcified lesions -SPACE 2 cartoid study is halted -Juan Perodi: A humble patient -Rocha-Singh: DEBs below-the-knee -Profile: Jean-Baptiste Ricco http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/65-Vascular-News-EU_low-res.pdf  
Leaving the devices in place risks filter fracture or symptoms from penetration of filter components outside of the vein into adjacent structures, increased risk of new blood clots in the legs, and other complications.
By David Dudzinski Transthoracic echocardiography offers real-time information that assists vascular specialists in the diagnostic and prognostic evaluation of acute pulmonary embolism. Specific roles of transthoracic echocardiography are subject to local practice and expertise as there is no formulaic approach...
By Ido Weinberg @Angiologist   The Merriam-Webster dictionary defines social media as “forms of electronic communication (as websites for social networking and microblogging) through which users create online communities to share information, ideas, personal messages, and other content (as videos).” So,...
Highlights: -C-arm angulation increases radiation exposure to operators during complex EVAR -EXCITE ISR results show superiority of laser atherectomy over angioplasty alone -Lutonix becomes first drug-eluting balloon to be approved in USA -Lindsay Machan: Reducing radiation -Ido Weinberg: Social...
Highlights: -C-arm angulation increases radiation exposure to operators during complex EVAR -EXCITE ISR results show superiority of laser atherectomy over angioplasty alone -Lutonix becomes first drug-eluting balloon to be approved in USA -Lindsay Machan: Reducing radiation -Ido Weinberg: Social...
Veniti has enrolled the first US patients in the VIRTUS trial of the Venti Vici venous stent system, with four procedures performed at two sites.
Cardinal Health has announced that its MynxGrip Vascular Closure Device recently received Food and Drug Administration (FDA) approval for use to close femoral veins. The MynxGrip device is now indicated for use to seal 5F, 6F and 7F femoral arterial and femoral venous access sites.
Highlights: -Two-stage TEVAR yields lower mortality and more protection against spinal cord injury -Endovascular repair of popliteal aneurysm maintains significant sac shrinkage at five years -Incraft low-profile endograft launched in Europe and Canada -Thomas Zeller: Drug-eluting balloons -Philip S...
Highlights: -Two-stage TEVAR yields lower mortality and more protection against spinal cord injury -Endovascular repair of popliteal aneurysm maintains significant sac shrinkage at five years -Incraft low-profile endograft launched in Europe and Canada -Thomas Zeller: Drug-eluting balloons -Philip S...
Novate Medical has announced that Souheil Saddekni, professor of Vascular and Interventional Radiology at the University of Alabama, Birmingham, USA, has enrolled the first patient in the SENTRY IDE study.
The Editors of the European Journal of Vascular and Endovascular Surgery have announced the introduction of a new Open Access, online journal to run alongside the existing journal.
Bristol-Myers Squibb and Pfizer have announced results of a pre-specified secondary analysis of the Eliquis phase 3 AMPLIFY-EXT trial (Apixaban after the initial management of pulmonary embolism and deep vein thrombosis with first-line therapy-extended treatment). The analysis evaluated clinical...
By Mark S Whiteley Since the NICE (National Institute for Health and Care Excellence) guidelines for the treatment of varicose veins was published in July 2013, endovenous thermal ablation has now “come of age”. Recommended as the first line treatment...
BTG International has announced that the first varicose vein patient has been treated with Varithena (polidocanol injectable foam), the only FDA-approved foam for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous...
Bristol‐Myers Squibb Company and Pfizer have announced that the European Commission has approved Eliquis (apixaban) for the treatment of deep vein thrombosis and pulmonary embolism, and the prevention of recurrent deep vein thrombosis and pulmonary embolism in adults. The...
A study published in the Journal of the American Medical Association (JAMA) has found no difference in mortality rates between deep vein thrombosis patients treated with catheter-directed thrombolysis or anticoagulation alone. In the study, evidence of higher adverse events...
Veniti has announced that it has received approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin the VIRTUS trial of the Vici venous stent system. The Vici venous stent system...
The Heart and Vascular Outcomes Research Institute (HVORI) is collaborating with a number of medical centres to launch the iRetrieve study aimed to improve the retrieval rate of inferior vena cava (IVC) filters. John E Rectenwald, associate professor of...
Covidien has announced the commercial launch of its next generation Trellis peripheral infusion system. The redesigned system continues to be the only pharmacomechanical thrombolysis device that enables focused treatment of blood clots that lead to post-thrombotic syndrome. This latest Trellis system has...
Highlights: -CX 2014 audience recognises the impact of drug-eluting balloons -No type I or III endoleaks with the Incraft system for EVAR at two years -Lindsay Machan: Radiation hazards -Mark S Whiteley: Heat ablation -Profile: Cliff Shearman http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/62-Vascular-News-USA_low-res.pdf
Highlights: -CX 2014 audience recognises the impact of drug-eluting balloons -No type I or III endoleaks with the Incraft system for EVAR at two years -Lindsay Machan: Radiation hazards -Mark S Whiteley: Heat ablation -Profile: Cliff Shearman http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/62-Vascular-News_low-res.pdf
Bristol-Myers Squibb Company and Pfizer have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Eliquis (apixaban) be granted marketing authorisation for the treatment...
EKOS Corporation has announced the start of patient enrolment for the Accelerated thrombolysis for post-thrombotic syndrome using the EkoSonic endovascular system (ACCESS PTS) study. The ACCESS PTS study is a prospective, single-arm, multicentre trial, designed to evaluate the safety and...
Boehringer Ingelheim has announced that Pradaxa (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism. The US Food and Drug Administration (FDA) approved Pradaxa for...
Cook Medical is engaged in two clinical studies that will provide additional data on the safety and effectiveness of inferior vena cava filters. The first study, the Cook Inferior Vena Cava Filter (CIVC) study, will add to Cook’s existing clinical...
Women with significant pelvic vein incompetence are likely to have haemorrhoids, which could suggest a causal link, according to research from a varicose vein clinic. Judy Holdstock (Whiteley Clinic, London) told the Charing Cross Symposium (5–8 April; London, UK) that...
Ekos Corporation has announced that the US Food and Drug Administration (FDA) has cleared the EkoSonic endovascular system for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism.
Stephen Black, St George’s Hospital, London, UK, told delegates at the Charing Cross Symposium (5–8 April 2014, London, UK) that most of the evidence for deep venous reconstruction is based on single-centre experiences, many of them small, and therefore...
Boehringer Ingelheim Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Pradaxa (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis and pulmonary embolism in patients who have been treated with a parenteral anticoagulant for...
At the CX Office-based Vein Practice Course, delegates were granted the unique opportunity to view demonstrations and try office-based venous devices and procedures with the guidance of experienced tutors. The 2014 CX Office-based Practice Course saw record attendance with...
Daiichi Sankyo announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation or venous thromboembolism enrolled in two phase 3 edoxaban studies. The findings of the two subgroup analyses of 1,943 East Asian...
Recognising that new technologies and techniques are revolutionising how venous disorders are treated, in 2014, for the first time, the Charing Cross Symposium (5–8 April, London, UK) will host three days of venous activities. This year, the CX Office-based...
Highlights: -No difference between endovascular and open repair for ruptured aneurysms -Renal artery stenting no better than medical therapy alone in CORAL -Hybrid techniques for the arch: are they effective and durable? By Piergiorgio Cao -Profile: Andrew Holden http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/61-Vascular-News_low-res_USA.pdf
Highlights: -No difference between endovascular and open repair for ruptured aneurysms -Renal artery stenting no better than medical therapy alone in CORAL-Hybrid techniques for the arch: are they effective and durable? By Piergiorgio Cao-Profile: Andrew Holden http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/61-Vascular-News_low-res.pdf
Veniti announced on 23 January 2014 that patients in the European Union (EU) were successfully treated for symptomatic venous outflow obstruction of the lower extremities with the Veniti Vici Venous Stent System. These procedures mark the first uses in...
EKOS Corporation announced on 20 January 2014 the publication of the results of its ULTIMA (Ultrasound accelerated thrombolysis of pulmonary embolism) trial in Circulation. The announcement was made at the International Symposium on Endovascular Therapy (ISET) in Miami, USA.   The ULTIMA...
Argon Medical Devices announced that it has received clearance from the US Food and Drug Administration to begin marketing the Option Elite retrievable inferior vena cava filter with a new over-the-wire delivery technique on 16 January 2013. According to the...
Sapheon has announced that it has submitted the second module of the pre-market approval (PMA) application for the VenaSeal Sapheon Closure System to the US Food and Drug Administration (FDA). According to the company, the submission, which was completed...
Daiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation and symptomatic venous thromboembolism. Daiichi Sankyo has announced that it has submitted a supplemental new drug application for its oral, once-daily direct factor Xa-inhibitor edoxaban (Lixiana)...
Boehringer Ingelheim has announced results from the RE-COVER II study evaluating dabigatran compared to warfarin in patients diagnosed with acute deep vein thrombosis and/or pulmonary embolism. In this phase III study, published online in the American Heart Association’s journal...

Lowell S Kabnick

Lowell S Kabnick, associate professor, NYU Langone Medical Center, New York, USA, has worked to develop minimally invasive systems for the treatment of varicose veins. His proudest moment was the development of the TreSheath device, which  carries the laser...
Highlights: -Vascular surgery societies refuse to endorse TASC III -ESVS announces bankruptcy of annual meeting organiser -3D contrast-enhanced ultrasound potentially better at detecting endoleaks -Profile: Lowell Kabnick
Highlights: -Vascular surgery societies refuse to endorse TASC III -ESVS announces bankruptcy of annual meeting organiser -3D contrast-enhanced ultrasound potentially better at detecting endoleaks -Profile: Lowell Kabnick
BTG has announced that the FDA has approved polidocanol injectable foam (Varithena) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein system. Varithena (formerly known as Varisolve PEM) is a pharmaceutical-grade, low-nitrogen, polidocanol...
Highlights: -Vascular surgery societies refuse to endorse TASC III -ESVS announces bankruptcy of annual meeting organiser -3D contrast-enhanced ultrasound potentially better at detecting endoleaks -Profile: Lowell Kabnick http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/60-Vascular-News_US.pdf
Highlights: -Vascular surgery societies refuse to endorse TASC III -ESVS announces bankruptcy of annual meeting organiser -3D contrast-enhanced ultrasound potentially better at detecting endoleaks -Profile: Lowell Kabnick     http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/60-Vascular-News_low-res.pdf
The company's Limerick site develops peripheral vascular, gastroenterology and urology devices for global distribution, and the Innovation Centre is a dedicated space enabling the company to collaborate closely with physicians.
The double helical, symmetrical design of the Crux device helps prevent filter tilt, as the helical design self-centres automatically within the vena cava upon deployment. The device offers the Bi-Trieval option of retrieval via either the jugular or femoral vein.
By Brian G DeRubertis   Surgical caval interruption for prevention of fatal pulmonary embolisation had been performed since the 1950s, though the modern era of pulmonary embolism prevention began with the introduction of the implantable inferior vena cava filters. Initial experience...
A new rotational thrombectomy device is safe and effective in the treatment of acute and subacute deep vein thrombosis in a single session of pharmacomechanical thrombolysis providing results of improved functional outcome. The results of a multicentre registry with the...
Researchers from Universite Laval’s Faculty of Medicine and CHU de Quebec have shown that it is possible to treat venous ulcers unresponsive to conventional treatment with wound dressings made from human skin grown in vitro. A study published in...
A UK national initiative to carry out mandatory screening of hospital patients for deep vein thrombosis has resulted in a “significant” reduction in death rates, experts in Birmingham have concluded. A major study was carried out involving every single patient admitted...
Highlights: -Inadequate sealing is top reason for endograft explant -"Aortic debranching safe and durable up to five years" -A unified voice for vascular surgery in Latin America by Alberto Munoz -Profile: Thomas Zeller http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/59-Vascular-News_USA.pdf
Highlights: -Inadequate sealing is top reason for endograft explant -"Aortic debranching safe and durable up to five years" -A unified voice for vascular surgery in Latin America by Alberto Munoz -Profile: Thomas Zeller http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/59-Vascular-News_low-res.pdf
Highlights: -Inadequate sealing is top reason for endograft explant -"Aortic debranching safe and durable up to five years" -A unified voice for vascular surgery in Latin America by Alberto Munoz -Profile: Thomas Zeller.
Highlights: -Inadequate sealing is top reason for endograft explant -"Aortic debranching safe and durable up to five years" -A unified voice for vascular surgery in Latin America by Alberto Munoz -Profile: Thomas Zeller.
LeMaitre Vascular has announced that it acquired the assets of InaVein for US$2.5mm, or 1.1X InaVein’s 2012 sales, and potential earn-out payments in 2014 and 2015 based on the performance of the acquired business and regulatory approval in China....
Results from the Hokusai-VTE study presented at the European Society of Cardiology (ESC) congress have shown that the oral anticoagulant edoxaban was non-inferior to warfarin in the treatment of venous thromboembolism (VTE). The randomised trial also demonstrated that the...
Sapheon announced on 9 September 2013 that it has completed enrolment in the US pivotal study of the VenaSeal Sapheon Closure System. According to the company, 242 patients have been enrolled in the study.   VenaSeal is a minimally invasive, single...
Tactile Medical has launched an ambulatory device for patients with chronic wounds. The ACTitouch Adaptive Compression Therapy system combines two proven therapies—intermittent and sustained compression—in one device to heal venous leg ulcers. Sustained compression has long been the standard of...
There is no evidence that impaired blood flow or blockage in the veins of the neck or head is involved in multiple sclerosis, says a study from McMaster University. The research, published online by PLOS ONE on 14 August 2013, found no evidence...
Haroun Gajraj, director of the The VeinCare Centre, Bristol, UK, speaks about using medical super glue for the treatment of varicose veins and superficial venous reflux.
Thermocoagulation with a new endovenous radiofrequency system is a safe and efficient technique in the treatment of reflux of the great saphenous vein, according to a pilot study conducted in Belgium.   Thermocoagulation with EVRF (F Care Systems) is a treatment...
Surgery should only be offered to treat varicose veins if other less invasive treatments are unsuitable for patients, according to a guidance issued by the UK National Institute for Health and Care Excellence (NICE) on 24 July. For the first...
A multicentre study has confirmed the effectiveness of intermittent pneumatic compression systems in reducing the incidence of deep vein thrombosis following a stroke. According to a press release, incidence could be reduced by 29%.
A review of the literature suggests there is insufficient evidence to support the use of intravascular filters or augmented dosing of anticlotting medication in patients undergoing bariatric surgery to prevent venous thromboembolism, according to a report published online first...
EKOS owns, manufactures and distributes the EkoSonic Endovascular System (EkoSonic), an interventional device that uses a locoregional approach in the treatment of severe blood clots.
Highlights: - Management of type II endoleak divides the experts at CX35 - Intermittent claudication: Lack of funding for supervised exercise programmes remains a global problem - First-in-man implantation of left subclavian artery branched TEVAR device http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/58-Vascular-News-US_low-res.pdf  
Highlights: - Management of type II endoleak divides the experts at CX35 - Intermittent claudication: Lack of funding for supervised exercise programmes remains a global problem - First-in-man implantation of left subclavian artery branched TEVAR device http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/58-Vascular-News.pdf
In the US study with the device, there was 100% freedom from aneurysm-related mortality, 0% post-implant aneurysm rupture, 0% graft migration and 0% conversion to open repair for the 107 patients followed to three years.
Highlights: - Management of type II endoleak divides the experts at CX35 - Intermittent claudication: Lack of funding for supervised exercise programmes remains a global problem - First-in-man implantation of left subclavian artery branched TEVAR device
Highlights: - Management of type II endoleak divides the experts at CX35 - Intermittent claudication: Lack of funding for supervised exercise programmes remains a global problem - First-in-man implantation of left subclavian artery branched TEVAR device
At CX35 (6–9 April, London, UK), Cees Wittens, Maastricht, The Netherlands, presented his experience with stents for deep vein occlusive disease. He told delegates that the ideal device should offer high radial force and high flexibility.  Wittens stated that stenting...
Gerard Stansby, Newcastle, UK, told delegates at CX35 (6–9 April 2013, London, UK) that the use of glue in varicose veins in safe and effective and that, if it continues to show good results, it will be a very...
The UK National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending rivaroxaban (Xarelto, Bayer Healthcare) as a clinically and cost-effective option for treating pulmonary embolism and preventing recurrent deep vein thrombosis and pulmonary embolism...
Cook Medical has launched the VIVO clinical research study to evaluate the safety and effectiveness of the Zilver Vena Venous Self-Expanding Stent in the treatment of symptomatic iliofemoral venous outflow obstruction. This disease is characterised by leg pain, throbbing,...
Highlights: -Intermittent claudication - Lack of funding for supervised exercise programmes is a global problem -Latin America comes to CX -Latest data from peripheral trials presented at CX35 -Substantial improvement in functional status with bioresorbable scaffold at 30 days
Highlights: -Experts sharply divided on type II endoleak challenge -Cordis launches Smart Flex stent at CX35 -Developments in imaging go under the scanner at CX35 -CX St George's Vascular Access Course explores new technologies and research
Highlights: -Clinical need drives intraoperative imaging to the next level -CX ilegx Collaboration embraces Electronic Endovascular Education -A completely percutaneous closure approach is feasible in most cases -Hands-on training and learning at the CX Office-Based Vein Practice Course
Gerard O'Sullivan, Galway, Ireland, CX35 delegates that computed tomography pulmonary angiography (CTPA) and CT venography are his preferred imaging modalities.
Results of the ULTIMA pulmonary embolism trial comparing endovascular therapy to standard of care were presented at the American College of Cardiology meeting in San Francisco, USA, by Nils Kucher, University Hospital, Bern, Switzerland.  ULTIMA is the world’s first randomised...
Highlights: -What to expect from CX35 -Advanced imaging technology at the heart of CX35 -CX35 provides record number of educational opportunities -Summary of Vascular News and Interventional News’ profiles 2012
The New England Journal of Medicine has published findings from the RE-MEDY and RE-SONATE trials investigating dabigatran etexilate (Pradaxa, Boehringer Ingelheim) in the long-term prevention of deep vein thrombosis (DVT) or pulmonary embolism (PE). The results demonstrate that Pradaxa 150mg...
By Mohsen Sharifi Percutaneous endovenous intervention (PEVI) is increasingly being used in the treatment of massive lower extremity deep vein thrombosis. It utilises a variety of treatment modalities including catheter-directed thrombolysis, various thrombectomy devices, balloon venoplasty and stenting. There is...
ALN (ALN Implants Chirurgicaux, France) announced the launching in the USA of its new ALN Vena Cava Filter with Hook, which recently received the CE mark and Food and Drug Administration (FDA) approval. The ALN Vena Cava Filter with Hook...
By Russell Samson Aspirin finds a role again Before the advent of more potent heparin, low molecular weight heparins and warfarin, aspirin was used extensively in the treatment and prevention of deep vein thrombophlebitis. However, these medications have largely replaced aspirin. Recently,...
Daiichi Sankyo Europe announced the enrolment of the first patient into the PREFER in VTE (Prevention of thromboembolic events – European registry in venous thromboembolism) study on 6 February 2013. PREFER in VTE is the first patient registry to...
Highlights:-Initial experience of total endovascular arch aneurysm exclusion is "encouraging"-Stroke associated with a threefold increased future mortality in CREST-Advances in drug therapy for the treatment of thrombophlebitis and pulmonary embolism-Profile: Peter Gloviczki http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/57-Vascular-News_USA_low-res.pdf
Highlights: -Initial experience of total endovascular arch aneurysm exclusion is "encouraging" -Stroke associated with a threefold increased future mortality in CREST -Advances in drug therapy for the treatment of thrombophlebitis and pulmonary embolism -Profile: Peter Gloviczki http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/57-Vascular-News_low-res.pdf  

Peter Gloviczki

Peter Gloviczki, professor of Surgery, College of Medicine, Mayo Clinic, Rochester, USA, is the president of the Society for Vascular Surgery (SVS) 2012–2013. Gloviczki, who started his career in Hungary, moved to the United States in 1981 to work...
Highlights:-Initial experience of total endovascular arch aneurysm exclusion is "encouraging"-Stroke associated with a threefold increased future mortality in CREST-Advances in drug therapy for the treatment of thrombophlebitis and pulmonary embolism-Profile: Peter Gloviczki
Highlights:-Initial experience of total endovascular arch aneurysm exclusion is "encouraging"-Stroke associated with a threefold increased future mortality in CREST-Advances in drug therapy for the treatment of thrombophlebitis and pulmonary embolism-Profile: Peter Gloviczki
The results of PEARL (Registry of AngioJet use in the peripheral vascular system), a phase II multicentre registry, led by Robert Lookstein, chief of interventional radiology, Mount Sinai Medical Center, New York, USA, have suggested that rheolytic pharmacomechanical thrombectomy...
Covidien announced the five-year results of the ClosureFast Long-Term European Multi-Center Study in patients with chronic venous insufficiency in December. The ClosureFast study was conducted prospectively at eight centres in Europe. The Venefit procedure (using the ClosureFast radiofrequency ablation...
On 3 December, Volcano Corporation announced it has signed an agreement to acquire Crux Biomedical, developer of the Crux VCF System―an inferior vena cava (IVC) filter designed to prevent pulmonary embolisms.The Crux VCF System, which is designed to facilitate bi-directional...
Highlights: -Early follow-up shows promising results with bioabsorbable stent in the superficial femoral artery -Is the Cotavance withdrawal in the USA a setback for drug-eluting balloons? -ACST-2 first results indicate carotid revascularisation is becoming safer -Profile: Piergiorgio Cao http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/56-Vascular-News-USA_low-res.pdf
Highlights: -Early follow-up shows promising results with bioabsorbable stent in the superficial femoral artery -Is the Cotavance withdrawal in the USA a setback for drug-eluting balloons? -ACST-2 first results indicate carotid revascularisation is becoming safer -Profile: Piergiorgio Cao http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/56-Vascular-News_low-res.pdf  
Rivaroxaban (Xarelto, Bayer HealthCare) has been approved by the European Commission for the treatment of pulmonary embolism (PE) and the prevention of recurrent deep vein thrombosis (DVT) and PE in adults. This approval makes rivaroxaban the only novel oral...
Highlights: -Early follow-up shows promising results with bioabsorbable stent in the superficial femoral artery -Is the Cotavance withdrawal in the USA a setback for drug-eluting balloons? -ACST-2 first results indicate carotid revascularisation is becoming safer -Profile: Piergiorgio Cao
Highlights: -Early follow-up shows promising results with bioabsorbable stent in the superficial femoral artery -Is the Cotavance withdrawal in the USA a setback for drug-eluting balloons? -ACST-2 first results indicate carotid revascularisation is becoming safer -Profile: Piergiorgio Cao
Low-dose aspirin prevents recurrent venous thromboembolism and major vascular events in patients with first unprovoked venous thromboembolism, results from the ASPIRE randomised controlled trial, presented at the American Heart Association Scientific Sessions (3–7 November, Los Angeles, USA) have shown....
On 2 November, the US Food and Drug Administration (FDA) expanded the approved use of rivaroxaban (Xarelto) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following...
The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of the oral anticoagulant rivaroxaban for the treatment of pulmonary embolism and prevention of recurrent pulmonary embolism and deep vein...
A computerised checklist system designed to help physicians identify and use the best methods of preventing potentially venous thromboembolism (VTE) in hospitalised trauma patients dramatically reduced the number of these dangerous VTEs, according to researchers from the Johns Hopkins...
Highlights:-Intensive endovascular simulation training improves performance-Stem cell mobilisation shows trend in improving amputation rate in critical limb ischaemia-Chimney and periscope grafts safe and effective to facilitate EVAR or hybrid procedures for complex aortic aneurysms-Profile: Frank Lederle
Highlights:-Intensive endovascular simulation training improves performance-Stem cell mobilisation shows trend in improving amputation rate in critical limb ischaemia-Chimney and periscope grafts safe and effective to facilitate EVAR or hybrid procedures for complex aortic aneurysms-Profile: Frank Lederle
Following Health Canada approval, Cook Medical announced the Canadian launch of the Zilver Vena Venous Self-Expanding Stent at the 2012 Annual Meeting of the Canadian Society for Vascular Surgery. The Zilver Vena is designed specifically for stenting obstructed iliofemoral...
On 3 October, the UK’ National Institute for Health and Clinical Excellence (NICE) opened a consultation on a new draft quality standard for the management of venous thromboembolic (VTE) diseases. The draft quality standard describes markers of high-quality, cost-effective...
Highlights: -Intensive endovascular simulation training improves performance -Stem cell mobilisation shows trend in improving amputation rate in critical limb ischaemia -Chimney and periscope grafts safe and effective to facilitate EVAR or hybrid procedures for complex aortic aneurysms -Profile: Frank...

Genetics of venous disease

By David L Gillespie Varicose veins are a common condition affecting more than 25 million people in the United States. While the genetic basis of varicose veins remains to be elucidated, it is clear they can arise in young individuals with...
Vascular Insights has announced the start of a multicentre randomised clinical trial conducted by principal investigators Alun H Davies, professor of Vascular Surgery and Ian J Franklin, consultant vascular surgeon, Imperial College London and Imperial College Healthcare NHS Trust.The...
Despite previous studies suggesting the contrary, statins may not prevent venous thrombo-embolism in adults, according to a large analysis by international researchers published recently in PLOS Medicine.
On 11 September 2012, Healthpoint Biotherapeutics announced the initiation of a phase III clinical trial investigating the efficacy of HP802-247 for the treatment of venous leg ulcers. HP802-247 is an investigational allogeneic living cell bioformulation containing keratinocytes and fibroblasts....
The new Crux inferior vena cava filter can be implanted and retrieved safely and shows a low rate of pulmonary embolism, Anthony J Comerota, director, Jobst Vascular Institute, adjunct professor of Surgery, University of Michigan, USA, told delegates at...
Sapheon announced one year data in a 38-patient clinical study of the VenaSeal Sapheon Closure System, an advanced approach to the treatment of saphenous vein disease based on a proprietary medical adhesive.All patients were treated without the use of...
Endovenous radiofrequency ablation is effective in the treatment of large diameter varicose veins irrespective of anatomical structure, according to a study presented by Andrey Petukhov, Research Institute of Experimental Medicine, Saint Petersburg, Russia, at the 13th Meeting of the...
Emily A Wood, Division of Vascular Surgery, Stony Brook University Medical Center, USA, spoke at the European Venous Forum Annual Meeting (28–30 June, Florence, Italy) on the results of a study that set out to quantify the incidence of...
The use of a new fibre for endovenous laser ablation of the great saphenous vein results in equal occlusion rates as achieved with a bare fibre, a new study shows. According to data presented at European Venous Forum (Florence,...
The US Food and Drug Administration (FDA) has cleared Crux Biomedical’s inferior vena cava filter with bi-directional retrieval for the prevention of pulmonary embolism. This feature allows retrieval of the device from the femoral or jugular veins, a key...
The use of ultrasound-accelerated catheter-directed thrombolysis to treat acute iliofemoral deep vein thrombosis continues to be feasible and safe, according to a study presented by Rob H W Strijkers (Department of Vascular Surgery and Cardiovascular Research Institute Masstricht, Maastricht...
The US Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental new drug applications (sNDAs) filed on 2 May 2012 for rivaroxaban  (Xarelto, Bayer/Janssen), an oral anticoagulant, seeking new indications to treat patients with...
Highlights: -Is the task for TASC III consensus too great? -World's first experience with a bioabsorbable stent for the superficial femoral artery presented at CX -Gene linked to abdominal aortic aneurysms is found -Profile: Ross Naylor http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/54-Vascular-News_low-res.pdf
On 27 June 2012, Covidien announced the launch of  its “1 in 1,000” campaign to help educate women about the risk of pregnancy-related blood clots, one of the leading causes of maternal mortality in the developed world.  The announcement...
New guidance published on 27 June 2012 by the UK National Institute for Health and Clinical Excellence (NICE) aims to reduce the current high toll of long-term ill health or death caused by venous thromboembolic diseases by clarifying for...
At two years, mechanochemical ablation (MOCA) is as efficacious as current endothermal techniques without the need of tumescent anaesthesia and is more effective than reported results of foam sclerotherapy of the great saphenous vein. Steve Elias, who presented the...
BiO2 Medical has announced that it has received CE mark approval for the Angel Catheter, a nitinol inferior vena cava (IVC) filter, permanently attached to a central venous catheter (CVC) for the use of preventing pulmonary embolism in critically...
Michael Gough, Leeds General Infirmary, Leeds, UK, presented long-term follow-up after endovenous laser ablation for great saphenous varicose veins at the 34th Charing Cross International Symposium in London, UK. The study reviewed a group of 63 patients (79 limbs)...
SEATTLE I and II are intended to further establish the safety and efficacy of ultrasound accelerated thrombolysis for treatment of pulmonary embolism.
On 16 March 2012, the Parliament gave statutory approval recognising vascular surgery as a specialty independent from general surgery in the United Kingdom.
Stryker’s Sustainability Solutions division has announced the launch of Restep, a compression sleeve for deep vein thrombosis treatment. Restep provides hospitals with a single-source opportunity for deep vein thrombosis compression sleeves and allows hospitals an opportunity to lower costs by...
Final guidance from the UK’s National Institute for Health and Clinical Excellence (NICE), released on 28 March, encourages further research into percutaneous venoplasty, a procedure which is claimed to relieve symptoms for some people with multiple sclerosis.The procedure aims...
Results of the EINSTEIN-PE study have shown that the oral anticoagulant rivaroxaban (Xarelto, Janssen and Bayer Healthcare) was comparable to today’s standard of care in treating patients with acute symptomatic pulmonary embolism and in preventing development of venous thromboembolism....
Mohsen Sharifi, adjunct associate professor of Medicine at A T Still University, Mesa, USA, presented new data demonstrating that percutaneous endovenous intervention (PEVI) is an alternative in the treatment of upper extremity deep vein thrombosis at the iCON meeting...
The majority of recurrences following thermal ablation for varicose veins are associated with perforating veins, results of the REVATA study have shown. The investigation involved 164 varicose vein patients who were treated with radiofrequency or endovenous laser ablation.The results...
Guering Eid-Lidt, Department of Interventional Cardiology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, spoke about long-term outcomes of percutaneous mechanical thrombectomy for severe pulmonary embolism at the iCON meeting in Arizona, USA.Eid-Lidt said that percutaneous mechanical thrombectomy...
The recommendations would authorise the FDA to collect US$595 million in user fees over five years, plus adjustments for inflation.
The US Food and Drug Administration FDA has granted 510(k) clearance to AngioDynamics to market its NeverTouch Direct Procedure Kit for use with the VenaCure EVLT Laser Vein Ablation System (AngioDynamics). The NeverTouch Direct offers physicians the ability to treat...
The anticoagulant rivaroxaban (Bayer HealthCare, Xarelto) has been accepted by the Scottish Medicines Consortium (SMC) for use in eligible patients within NHS Scotland in two new therapeutic indications, based on licences granted by the European Commission: The prevention of stroke...
Vascular Solutions announced that it is marketing a reprocessing service for the ClosureFAST radiofrequency ablation catheter in the United States. The ClosureFAST catheter, which is manufactured and marketed by VNUS Medical Technologies, is widely used for performing endovenous therapy...
Highlights: -Are "off-the-shelf" fenestrated endografts seeing a new dawn? -Lower restenosis and re-occlusion rates with drug-eluting balloons compared to angioplasty in DEBATE-BTK -Dismantling the different myths around the CREST trial -Profile: Patrick Peeters http://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2016/02/53-Vascular-News_low-res.pdf
By Jörn Oliver Balzer Pulmonary embolism continues to be a major cause of morbidity and mortality in the United States. In most clinical situations, anticoagulation is the preferred form of therapy. The efficacy of inferior vena cava filters is still...
Crux Biomedical announced it has received CE mark approval for their inferior vena cava filter (IVCF) with bi-directional retrieval (BDR). The Crux Biomedical IVCF was designed to address the limitations of currently available vena cava filters including perforation, migration and...
Sapheon announced one year results in its first in-man safety trial of the Sapheon Closure system. At the one year mark, 100% of the great saphenous vein segments treated with this vein sealant remained completely closed by ultrasound criteria....
The Centers for Medicare and Medicaid Services (CMS) has issued proposed regulatory guidance for implementing the Physician Payments Sunshine Act developed by senators Herb Kohl and Chuck Grassley in the USA.
Researchers from Norway have found that additional treatment with catheter-directed thrombolysis (CDT), when compared to standard treatment of oral anticoagulation therapy and elastic compression stockings, reduces the risk of post-thrombotic syndrome (PTS) in patients who suffer from deep-vein thrombosis...
Bluegrass Vascular Technologies has announced patient enrolment in the first clinical study of its Surfacer Inside-Out access catheter system, a proprietary system that allows physicians to perform a novel “inside-out” approach to gain venous access. The prospective single-centre feasibility study...
On 12 December, Daiichi Sankyo announced the results of a pooled analysis showing that edoxaban, a direct oral once-daily Factor Xa inhibitor, significantly reduced the risk of developing venous thromboembolism (VTE) following total knee or hip arthroplasty, when compared...